Targeted therapies for hepatocellular carcinoma

Jonas W. Feilchenfeldt, Eileen M. O'Reilly, Costantine Albany, Ghassan K. Abou-Alfa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance.

Original languageEnglish (US)
Title of host publicationHepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care
PublisherSpringer New York
Pages355-368
Number of pages14
ISBN (Print)9781603275217
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Drug Resistance
Hepatocellular Carcinoma
Poisons
Liver
Multiple Drug Resistance
Xenobiotics
Hepatocytes
Cell Line
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • Bevacizumab
  • Erlotinib
  • HCC etiology
  • HCC targeted therapies
  • Sorafenib
  • Sunitinib
  • Tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feilchenfeldt, J. W., O'Reilly, E. M., Albany, C., & Abou-Alfa, G. K. (2011). Targeted therapies for hepatocellular carcinoma. In Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care (pp. 355-368). Springer New York. https://doi.org/10.1007/978-1-60327-522-4_22

Targeted therapies for hepatocellular carcinoma. / Feilchenfeldt, Jonas W.; O'Reilly, Eileen M.; Albany, Costantine; Abou-Alfa, Ghassan K.

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. Springer New York, 2011. p. 355-368.

Research output: Chapter in Book/Report/Conference proceedingChapter

Feilchenfeldt, JW, O'Reilly, EM, Albany, C & Abou-Alfa, GK 2011, Targeted therapies for hepatocellular carcinoma. in Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. Springer New York, pp. 355-368. https://doi.org/10.1007/978-1-60327-522-4_22
Feilchenfeldt JW, O'Reilly EM, Albany C, Abou-Alfa GK. Targeted therapies for hepatocellular carcinoma. In Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. Springer New York. 2011. p. 355-368 https://doi.org/10.1007/978-1-60327-522-4_22
Feilchenfeldt, Jonas W. ; O'Reilly, Eileen M. ; Albany, Costantine ; Abou-Alfa, Ghassan K. / Targeted therapies for hepatocellular carcinoma. Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care. Springer New York, 2011. pp. 355-368
@inbook{69261a6e9a414d54a7103894a2d0cf8e,
title = "Targeted therapies for hepatocellular carcinoma",
abstract = "The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance.",
keywords = "Bevacizumab, Erlotinib, HCC etiology, HCC targeted therapies, Sorafenib, Sunitinib, Tyrosine kinase inhibitors (TKIs)",
author = "Feilchenfeldt, {Jonas W.} and O'Reilly, {Eileen M.} and Costantine Albany and Abou-Alfa, {Ghassan K.}",
year = "2011",
doi = "10.1007/978-1-60327-522-4_22",
language = "English (US)",
isbn = "9781603275217",
pages = "355--368",
booktitle = "Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care",
publisher = "Springer New York",

}

TY - CHAP

T1 - Targeted therapies for hepatocellular carcinoma

AU - Feilchenfeldt, Jonas W.

AU - O'Reilly, Eileen M.

AU - Albany, Costantine

AU - Abou-Alfa, Ghassan K.

PY - 2011

Y1 - 2011

N2 - The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance.

AB - The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance.

KW - Bevacizumab

KW - Erlotinib

KW - HCC etiology

KW - HCC targeted therapies

KW - Sorafenib

KW - Sunitinib

KW - Tyrosine kinase inhibitors (TKIs)

UR - http://www.scopus.com/inward/record.url?scp=84890002918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890002918&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-522-4_22

DO - 10.1007/978-1-60327-522-4_22

M3 - Chapter

SN - 9781603275217

SP - 355

EP - 368

BT - Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care

PB - Springer New York

ER -